, related to Figure 3 . A) Erk5+/+ or Erk5-/-mESCs were transfected with either empty vector or Erk5 cDNA, and Klf2 mRNA (left panel) or Erk5 and Erk1/2 expression (right panel) determined by immunoblotting. Data are represented as average ± SD from a representative experiment (n=3). B) Erk5+/+ mESCs were treated with indicated concentrations of Mek5 inhibitor BIX 02189 or Erk5 inhibitor JWG-071. Klf2 and Erk5 levels were determined by immunoblotting (n=3). C) Erk5+/+ mESCs were transfected with empty vector or Mek5DD cDNA and Fgf5 mRNA levels at indicated days post transfection determined by qRT-PCR. The ratio of Mek5DD/Control is represented as average ± SD from 3 independent experiments. D) Erk5-/-mESCs were transfected with either empty vector or Erk5 cDNA, and Klf4, Erk5 and Erk1/2 expression determined by immunoblotting (n=3). E) Erk5+/+ or Erk5-/-mESCs were LIF deprived for the indicated time and Klf4, Erk5 and Erk1/2 expression determined by immunoblotting. Intervening lanes were removed, as indicated by a dotted line (n=3). Supplemental Tables   Table S1 . Full list of primed hits from screen, related to Figure 1 Primed Hits (<0. 
